Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RAI SERVICES COMPANY · Firm: CGCN GROUP, LLC
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RAI SERVICES COMPANY · Firm: CGCN GROUP, LLC
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2026 · third_quarter · Q3
Issues related to the nursing workforce, scientific research and health technology.
Issues related to promoting Medicaid program integrity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| 2 |
| 2026 |
| THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION | 2 | 2026 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | 2026 |
| EMERGENT BIOSOLUTIONS INC. | 1 | 2026 |
| MANUS BIO INC. | 1 | 2026 |
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CGCN GROUP, LLC
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CGCN GROUP, LLC
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Lower Costs, More Transparency Act of 2026
Client: PARKVIEW HEALTH SYSTEM, INC. · Firm: CGCN GROUP, LLC
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
Lower Costs, More Transparency Act of 2026
Client: PARKVIEW HEALTH SYSTEM, INC. · Firm: CGCN GROUP, LLC
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
National Defense Authorization Act for Fiscal Year 2026
Client: FUJIFILM HOLDINGS AMERICA CORPORATION · Firm: CGCN GROUP, LLC
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
National Defense Authorization Act for Fiscal Year 2026
Client: FUJIFILM HOLDINGS AMERICA CORPORATION · Firm: CGCN GROUP, LLC
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Connected Vehicle Security Act of 2026
Client: THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION · Firm: CGCN GROUP, LLC
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles, auto parts supply chains, and importation; S. 4429 Connected Vehicle Security Act.
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
American Relief Act, 2025
Client: FUJIFILM HOLDINGS AMERICA CORPORATION · Firm: CGCN GROUP, LLC
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
American Relief Act, 2025
Client: FUJIFILM HOLDINGS AMERICA CORPORATION · Firm: CGCN GROUP, LLC
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
No Tax Subsidies for E-Cigarette and Tobacco Ads Act
Client: RAI SERVICES COMPANY · Firm: CGCN GROUP, LLC
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
No Tax Subsidies for E-Cigarette and Tobacco Ads Act
Client: RAI SERVICES COMPANY · Firm: CGCN GROUP, LLC
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
2026 · third_quarter · Q3
Implementation of P.L. 111-31, the Tobacco Control Act; Issues surrounding FDA PMTA and MRTP compliance policies; Issues surrounding tobacco harm reduction; Issues surrounding efforts to prevent youth access to tobacco products; Discussions in support of the regulation of products containing synthetic nicotine and disposable e-cigarettes; Issues surrounding increased scrutiny on FDA/CTP for delayed enforcement; Issues surrounding CBP resources for interdicting massive influx & mislabeling illicit vapes; Issues surrounding retail inspections enforcement limitation; Issues surrounding implementation of P.L. 111-31, the Tobacco Control Act; NPRM for Docket No. FDA-2021-N-1349: Tobacco Product Standard for Menthol in Cigarettes; January 2025 Proposed Rule: Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products; Issues surrounding efforts to prevent youth access to tobacco products; Discussions regarding federal excise taxes and the taxation of tobacco products; Discussions regarding FDA enforcement of flavored disposable e-cigarettes and PMTA transparency.
Discussions concerning the FY 2025 and FY 2026 appropriations bills; provisions related to the FDA regulation of tobacco.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARKVIEW HEALTH SYSTEM, INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, White House Office
THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles, auto parts supply chains, and importation; S. 4429 Connected Vehicle Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via CGCN GROUP, LLC
2026 · third_quarter · Q3
Access to innovative non-opioid medicines.
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FUJIFILM HOLDINGS AMERICA CORPORATION via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to trade and tariffs.
Issues related to domestic chemical manufacturing.
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
MANUS BIO INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues pertaining to onshoring of biotechnology manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA, LLC via CGCN GROUP, LLC
2026 · third_quarter · Q3
Section 232 investigation into pharmaceuticals and unfair trade practices.
U.S. manufacturing incentives.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
EMERGENT BIOSOLUTIONS INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
PHOTOCURE INC. via CGCN GROUP, LLC
2026 · third_quarter · RR
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
RAI SERVICES COMPANY via CGCN GROUP, LLC
2026 · second_quarter · Q2
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles, auto parts supply chains, and importation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
FRESENIUS KABI USA, LLC via CGCN GROUP, LLC
2026 · second_quarter · Q2
Section 232 investigation into pharmaceuticals and unfair trade practices.
U.S. manufacturing incentives.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
FUJIFILM HOLDINGS AMERICA CORPORATION via CGCN GROUP, LLC
2026 · second_quarter · Q2
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
Issues related to trade and tariffs.
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via CGCN GROUP, LLC
2026 · second_quarter · Q2
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Access to innovative non-opioid medicines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · second_quarter · Q2
Issues related to the nursing workforce, scientific research and health technology.
Issues related to promoting Medicaid program integrity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARKVIEW HEALTH SYSTEM, INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, White House Office
Support for biopharmaceutical manufacturing in the U.S.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Buy America legislation, tariffs, and tax incentives.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Implementation of P.L. 111-31, the Tobacco Control Act; Issues surrounding FDA PMTA and MRTP compliance policies; Issues surrounding tobacco harm reduction; Issues surrounding efforts to prevent youth access to tobacco products; Discussions in support of the regulation of products containing synthetic nicotine and disposable e-cigarettes; Issues surrounding increased scrutiny on FDA/CTP for delayed enforcement; Issues surrounding CBP resources for interdicting massive influx & mislabeling illicit vapes; Issues surrounding retail inspections enforcement limitation; Issues surrounding implementation of P.L. 111-31, the Tobacco Control Act; NPRM for Docket No. FDA-2021-N-1349: Tobacco Product Standard for Menthol in Cigarettes; January 2025 Proposed Rule: Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products; Issues surrounding efforts to prevent youth access to tobacco products; Discussions regarding federal excise taxes and the taxation of tobacco products; Discussions regarding FDA enforcement of flavored disposable e-cigarettes and PMTA transparency.
Discussions concerning the FY 2025 and FY 2026 appropriations bills; provisions related to the FDA regulation of tobacco.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Buy America legislation, tariffs, and tax incentives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Support for biopharmaceutical manufacturing in the U.S.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Issues related to domestic chemical manufacturing.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office